TherapeuticsMD Inc (NASDAQ:TXMD) shares reached a new 52-week low on Friday . The stock traded as low as $2.21 and last traded at $2.22, with a volume of 578798 shares. The stock had previously closed at $2.27.
Several research analysts have weighed in on TXMD shares. Zacks Investment Research downgraded shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Jefferies Financial Group set a $189.00 price objective on shares of salesforce.com and gave the stock a “buy” rating in a report on Monday. Noble Financial restated an “outperform” rating and set a $13.00 price objective on shares of TherapeuticsMD in a report on Tuesday, April 30th. ValuEngine upgraded shares of Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, BidaskClub upgraded shares of Winmark from a “sell” rating to a “hold” rating in a report on Tuesday, May 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $9.28.
The company has a market cap of $547.57 million, a P/E ratio of -3.75 and a beta of 1.88. The business’s 50-day moving average price is $2.70. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.28 and a current ratio of 3.39.
A number of large investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY boosted its position in TherapeuticsMD by 8.2% during the first quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock worth $296,000 after purchasing an additional 4,627 shares during the period. Beaumont Financial Partners LLC boosted its position in shares of TherapeuticsMD by 19.5% in the first quarter. Beaumont Financial Partners LLC now owns 35,000 shares of the company’s stock valued at $170,000 after acquiring an additional 5,700 shares during the period. Greenwood Capital Associates LLC boosted its position in shares of TherapeuticsMD by 2.2% in the first quarter. Greenwood Capital Associates LLC now owns 278,858 shares of the company’s stock valued at $1,358,000 after acquiring an additional 5,947 shares during the period. New York State Common Retirement Fund boosted its position in shares of TherapeuticsMD by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 179,100 shares of the company’s stock valued at $682,000 after acquiring an additional 7,000 shares during the period. Finally, Private Ocean LLC bought a new position in shares of TherapeuticsMD in the first quarter valued at approximately $37,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.
About TherapeuticsMD (NASDAQ:TXMD)
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Article: How to calculate compound interest
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.